Abstract
During replication, HIV-1 reverse transcriptase lacks proof reading activity and is error prone. In addition APOBEC-driven hypermutation of HIV-1 Gag and Pol genes may generate replication-deficient viral variants with inframe stop codons. Virus variants with several stop codons in the RT gene were identified in a subject with residual HIV- 1 replication during antiretroviral treatment. A role for the T-cell response in the selection of replication-deficient variants was hypothesized. Clonal analysis of HIV-1 DNA and RNA sequences from three sequential blood samples was performed. Moreover, the HIV-1-specific memory CD8+ T-cell response was investigated using a peptide-based cultured ELISPOT assay. The accumulation of HIV-1 variants with stop codons in the Pol gene (from 0% to 100%) was observed in sequential plasma samples. The cultured ELISPOT showed a sustained response to a Pol region downstream from the last stop codon. A more detailed analysis of the Pol region encompassing the detected stop codons showed a strong response to a peptide at the end of the RT region containing stop codons (positions 206 to 220) and including the last stop codon (212). These results suggest a role for a peptide-specific immunologic response in the positive selection of cells expressing the truncated HIV-1 RT and the accumulation of replication-deficient viral variants in plasma. The antigenspecific CD8+ T-cell response could be exploited to redirect the response to HIV-1 infection toward in vivo selection of viral variants with reduced or abolished pathogenicity.
Keywords: RT stop codons, replication-deficient HIV-1, CD8+ T-cell response, cultured ELISPOT, APOBEC
Current HIV Research
Title: HIV-1 Plasma Variants Encoding Truncated Reverse Transcriptase (RT) in a Patient With High RT-Specific CD8+ Memory T-Cell Response
Volume: 7 Issue: 3
Author(s): Stefania Paolucci, Andrea Foli, Roberto Gulminetti, Sandra A. Calarota, Renato Maserati, Fausto Baldanti and Giuseppe Gerna
Affiliation:
Keywords: RT stop codons, replication-deficient HIV-1, CD8+ T-cell response, cultured ELISPOT, APOBEC
Abstract: During replication, HIV-1 reverse transcriptase lacks proof reading activity and is error prone. In addition APOBEC-driven hypermutation of HIV-1 Gag and Pol genes may generate replication-deficient viral variants with inframe stop codons. Virus variants with several stop codons in the RT gene were identified in a subject with residual HIV- 1 replication during antiretroviral treatment. A role for the T-cell response in the selection of replication-deficient variants was hypothesized. Clonal analysis of HIV-1 DNA and RNA sequences from three sequential blood samples was performed. Moreover, the HIV-1-specific memory CD8+ T-cell response was investigated using a peptide-based cultured ELISPOT assay. The accumulation of HIV-1 variants with stop codons in the Pol gene (from 0% to 100%) was observed in sequential plasma samples. The cultured ELISPOT showed a sustained response to a Pol region downstream from the last stop codon. A more detailed analysis of the Pol region encompassing the detected stop codons showed a strong response to a peptide at the end of the RT region containing stop codons (positions 206 to 220) and including the last stop codon (212). These results suggest a role for a peptide-specific immunologic response in the positive selection of cells expressing the truncated HIV-1 RT and the accumulation of replication-deficient viral variants in plasma. The antigenspecific CD8+ T-cell response could be exploited to redirect the response to HIV-1 infection toward in vivo selection of viral variants with reduced or abolished pathogenicity.
Export Options
About this article
Cite this article as:
Paolucci Stefania, Foli Andrea, Gulminetti Roberto, Calarota A. Sandra, Maserati Renato, Baldanti Fausto and Gerna Giuseppe, HIV-1 Plasma Variants Encoding Truncated Reverse Transcriptase (RT) in a Patient With High RT-Specific CD8+ Memory T-Cell Response, Current HIV Research 2009; 7(3) . https://dx.doi.org/10.2174/157016209788347930
DOI https://dx.doi.org/10.2174/157016209788347930 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Neuroprotection of (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Against Hydrogen Peroxide and Lipopolysaccharide Induced Injury via Modulating Arachidonic Acid Network and p38-MAPK Signaling
Current Alzheimer Research ACKNOWLEDGEMENTS TO REVIEWERS
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Development of New Drugs for COPD
Current Medicinal Chemistry Brief Psychotic Disorder during COVID-19 Infection: Marked Stressor or Neuropsychiatric Symptoms?
Current Psychiatry Research and Reviews Pharmacokinetics Prediction and Drugability Assessment of Diphenylheptanoids from Turmeric (Curcuma longa L)
Medicinal Chemistry Effects of Structured Treatment Interruptions on Metabolic, Anthropometric, Immunologic, and Quality of Life Outcomes in HIV-Positive Adults on HAART
Current HIV Research Inhibitors and Modulators of β- and γ-Secretase
Current Topics in Medicinal Chemistry The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Lentiviral Vectors for Gene Therapy of HIV-1 Infection
Current Gene Therapy Current Evidence on the Evaluation and Management of Fever Without a Source in Infants Aged 0-90 Days: A Review
Reviews on Recent Clinical Trials The Finely Regulating Well-defined Functional Polymeric Nanocarriers for Anti-tumor Immunotherapy
Mini-Reviews in Medicinal Chemistry Dextran-based Nanocarriers for Delivery of Bioactives
Current Pharmaceutical Design Targeted Gene Therapy for Ovarian Cancer
Current Gene Therapy Mechanisms of Activation and Key Roles of SGK3 Under Physiological Conditions and in Prostate and Breast Cancer
Current Signal Transduction Therapy Current Targets for Anticancer Drug Discovery
Current Drug Targets Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Diabetic Retinopathy in Pregnancy
Current Diabetes Reviews